G1 Therapeutics Inc

NASDAQ GTHX

Data sourced from

and

Download Data

G1 Therapeutics Inc Quick Ratio 3 year CAGR for the quarter ending March 31, 2024: -39.51%

G1 Therapeutics Inc Quick Ratio 3 year CAGR is -39.51% for the quarter ending March 31, 2024, a -73.04% change year over year. The quick ratio, also known as the acid-test ratio, measures a company's ability to meet its short-term obligations using its most liquid assets. It is calculated by dividing the current assets minus inventory by the current liabilities. This ratio provides insights into the company's liquidity position and its ability to pay off current liabilities without relying on inventory sales. A higher ratio suggests a stronger ability to meet short-term obligations with readily available assets. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

G1 Therapeutics Inc Quick Ratio for the quarter ending March 31, 2023 was 4.11, a -28.30% change year over year.
G1 Therapeutics Inc Quick Ratio for the quarter ending March 31, 2022 was 5.73, a -50.36% change year over year.
G1 Therapeutics Inc Quick Ratio for the quarter ending March 31, 2021 was 11.54.

NASDAQ: GTHX

G1 Therapeutics Inc

CEO	Mr. John E. Bailey Jr.
IPO Date	May 17, 2017
Location	United States
Headquarters	700 Park Offices Drive, Research Triangle Park, NC, United States, 27709
Employees	100
Sector	Healthcare
Industry	Biotechnology

Description

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Key trends